Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:HELP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$13.39+1.5%$12.09$3.50▼$15.40$1.81B2.473.73 million shs2.79 million shsHELPCybin$6.68-0.3%$5.08$3.76▼$9.12$460.92M0.621.00 million shs705,308 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways-3.30%+2.73%+9.19%+129.39%+259.40%HELPCybin-2.47%+13.75%+55.81%+22.71%+669,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$13.39+1.5%$12.09$3.50▼$15.40$1.81B2.473.73 million shs2.79 million shsHELPCybin$6.68-0.3%$5.08$3.76▼$9.12$460.92M0.621.00 million shs705,308 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways-3.30%+2.73%+9.19%+129.39%+259.40%HELPCybin-2.47%+13.75%+55.81%+22.71%+669,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCompass Pathways 2.94Moderate Buy$24.1580.39% UpsideHELPCybin 3.00Buy$55.00723.35% UpsideCurrent Analyst Ratings BreakdownLatest CMPS and HELP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026CMPSCompass Pathways HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.007/8/2026CMPSCompass Pathways EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$21.007/7/2026CMPSCompass Pathways Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $21.007/7/2026CMPSCompass Pathways Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/7/2026CMPSCompass Pathways Compass PointSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.007/7/2026CMPSCompass Pathways OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.007/7/2026CMPSCompass Pathways Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/7/2026CMPSCompass Pathways Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$17.007/7/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $25.006/26/2026CMPSCompass Pathways Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/AHELPCybinN/AN/AN/AN/A$4.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)HELPCybin-$148M-$4.23N/AN/AN/AN/A-68.27%-58.26%N/ALatest CMPS and HELP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026CMPSCompass Pathways-$0.3857N/AN/AN/AN/AN/A6/29/2026Q4 2026HELPCybinN/AN/AN/AN/AN/AN/A5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCompass PathwaysN/AN/AN/AN/AN/AHELPCybinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCompass Pathways0.153.323.32HELPCybinN/A9.529.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCompass Pathways46.19%HELPCybin17.94%Insider OwnershipCompanyInsider OwnershipCMPSCompass Pathways2.82%HELPCybin15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableHELPCybin5069.00 million58.65 millionN/ACMPS and HELP HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Forecast for Cybin FY2027 Earnings?July 13 at 1:26 AM | marketbeat.comWhat is HC Wainwright's Estimate for Cybin Q1 Earnings?July 10, 2026 | marketbeat.comHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsJune 29, 2026 | globenewswire.comCybin: A Speculative Bet On Their Pivotal Depression ReadoutJune 27, 2026 | seekingalpha.comCybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?June 26, 2026 | finance.yahoo.comHelus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug PipelineJune 25, 2026 | tipranks.comHelus Pharma™ Announces Closing of US$50 Million Underwritten OfferingJune 25, 2026 | globenewswire.comHelus Pharma™ Announces US$50 Million Underwritten OfferingJune 24, 2026 | globenewswire.comHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment ProgressJune 24, 2026 | globenewswire.comHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives ConferenceJune 11, 2026 | globenewswire.comHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New YorkJune 1, 2026 | globenewswire.comCORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 30, 2026 | globenewswire.comHelus Pharma to Participate at the 29th Annual Milken Institute Global ConferenceApril 30, 2026 | globenewswire.comHelus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 28, 2026 | globenewswire.comDoes Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?April 25, 2026 | finance.yahoo.comHelus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen BrannanApril 23, 2026 | globenewswire.comCybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)April 22, 2026 | seekingalpha.comPsychedelic drug stocks soar as Trump fast‑tracks FDA reviewsApril 20, 2026 | usatoday.comHow Trump's psychedelics executive order could unlock stalled cannabis reformApril 20, 2026 | cnbc.comPsychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gainsApril 20, 2026 | msn.comCybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD researchApril 20, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS and HELP Company DescriptionsCompass Pathways NASDAQ:CMPS$13.39 +0.20 (+1.52%) Closing price 04:00 PM EasternExtended Trading$13.35 -0.04 (-0.30%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Cybin NASDAQ:HELP$6.68 -0.02 (-0.30%) Closing price 04:00 PM EasternExtended Trading$6.77 +0.09 (+1.35%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
